@article{1af9ba0d391f43c5a54288b8e1895faa,
title = "Erratum: Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation; a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research",
abstract = "The authors inadvertently included grant numbers OT3HL147741 & U24CA233032, which are grant-specific. This was an oversight on the authors{\textquoteright} part as these grants did not support the research in this publication.",
author = "Aleksandr Lazaryan and Michelle Dolan and Zhang, {Mei Jie} and Wang, {Hai Lin} and Kharfan-Dabaja, {Mohamed A.} and Marks, {David I.} and Nelli Bejanyan and Edward Copelan and Majhail, {Navneet S.} and Waller, {Edmund K.} and Nelson Chao and Tim Prestidge and Taiga Nishihori and Partow Kebriaei and Yoshihiro Inamoto and Betty Hamilton and Hashmi, {Shahrukh K.} and Kamble, {Rammurti T.} and Ulrike Bacher and Hildebrandt, {Gerhard C.} and Stiff, {Patrick J.} and Joseph McGuirk and Ibrahim Aldoss and Beitinjaneh, {Amer M.} and Lori Muffly and Ravi Vij and Olsson, {Richard F.} and Michael Byrne and Schultz, {Kirk R.} and Mahmoud Aljurf and Matthew Seftel and Savoie, {Mary Lynn} and Savani, {Bipin N.} and Verdonck, {Leo F.} and Cairo, {Mitchell S.} and Nasheed Hossain and Bhatt, {Vijaya Raj} and Frangoul, {Haydar A.} and Hisham Abdel-Azim and {Al Malki}, Monzr and Reinhold Munker and David Rizzieri and Nandita Khera and Ryotaro Nakamura and Olle Ringd{\'e}n and {Van Der Poel}, Marjolein and Murthy, {Hemant S.} and Hongtao Liu and Shahram Mori and {De Oliveira}, Satiro and {Acute Leukemia Committee of the CIBMTR}",
note = "Funding Information: The CIBMTR is supported primarily by a public health service grant/cooperative agreement U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); grant/cooperative agreement U24HL138660 from the NHLBI and NCI; grants R21HL140314 and U01HL128568 from the NHLBI; a contract HHSH250201700006C with Health Resources and Services Administration (HRSA/DHHS); grants N00014-18-1-2888 and N00014-17-1-2850 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals, Inc.; Adaptive Biotechnologies; *Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; *Anthem, Inc.; Astellas Pharma US; Atara Biotherapeutics, Inc.; Be the Match Foundation; *bluebird bio, Inc.; Boston Children{\textquoteright}s Hospital; *Bristol Myers Squibb Co.; *Celgene Corp.; Children{\textquoteright}s Hospital of Los Angeles; *Chimerix, Inc.; *CSL Behring; *CytoSen Therapeutics, Inc.; Dana Farber Cancer Institute; *Daiichi Sankyo Co., Ltd.; Fred Hutchinson Cancer Research Center; *Gamida-Cell, Ltd.; Gilead Sciences, Inc.; *GlaxoSmithKline (GSK); HistoGenetics, Inc.; Immucor; Incyte Corporation; Janssen Biotech, Inc.; *Janssen Pharmaceuticals, Inc.; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Karius, Inc.; Karyopharm Therapeutics, Inc.; *Kite, a Gilead Company; *Magenta Therapeutics; Medac GmbH; The Medical College of Wisconsin; Mediware; Merck & Company, Inc.; *Mesoblast; MesoScale Diagnostics, Inc.; Millennium, the Takeda Oncology Co.; *Miltenyi Biotec, Inc.; Mundipharma EDO; National Marrow Donor Program; Novartis Oncology; Novartis Pharmaceuticals Corporation; *Omeros Corporation; *Oncoimmune, Inc.; PCORI; *Pfizer, Inc.; *Phamacyclics, LLC; PIRCHE AG; *Regeneron Pharmaceuticals, Inc.; REGiMMUNE Corp.; *Sanofi Genzyme; *Seattle Genetics; *Shire; Sobi, Inc.; Spectrum Pharmaceuticals, Inc.; St. Baldrick's Foundation; Swedish Orphan Biovitrum, Inc.; *Takeda Oncology; University of Minnesota; University of Pittsburgh; University of Texas-MD Anderson; University of Wisconsin – Madison and Viracor Eurofins. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government. *Corporate Members. Funding Information: The CIBMTR is supported primarily by a public health service grant/cooperative agreement U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); grant/cooperative agreement U24HL138660 from the NHLBI and NCI; grant U24CA233032 from the NCI; grants OT3HL147741, R21HL140314 and U01HL128568 from the NHLBI; a contract HHSH250201700006C with Health Resources and Services Administration (HRSA/DHHS); grants N00014-18-1-2888 and N00014-17-1-2850 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals, Inc.; Adaptive Biotechnologies; *Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; *Anthem, Inc.; Astellas Pharma US; Atara Biotherapeutics, Inc.; Be the Match Foundation; *bluebird bio, Inc.; Boston Children{\textquoteright}s Hospital; *Bristol Myers Squibb Co.; *Celgene Corp.; Children{\textquoteright}s Hospital of Los Angeles; *Chimerix, Inc.; *CSL Behring; *CytoSen Therapeutics, Inc.; Dana Farber Cancer Institute; *Daiichi Sankyo Co., Ltd.; Fred Hutchinson Cancer Research Center; *Gamida-Cell, Ltd.; Gilead Sciences, Inc.; *GlaxoSmithKline (GSK); HistoGenetics, Inc.; Immucor; Incyte Corporation; Janssen Biotech, Inc.; *Janssen Pharmaceuticals, Inc.; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Karius, Inc.; Karyopharm Therapeutics, Inc.; *Kite, a Gilead Company; *Magenta Therapeutics; Medac GmbH; The Medical College of Wisconsin; Mediware; Merck & Company, Inc.; *Mesoblast; MesoScale Diagnostics, Inc.; Millennium, the Takeda Oncology Co.; *Miltenyi Biotec, Inc.; Mundipharma EDO; National Marrow Donor Program; Novartis Oncology; Novartis Pharmaceuticals Corporation; *Omeros Corporation; *Oncoimmune, Inc.; PCORI; *Pfizer, Inc.; *Phamacyclics, LLC; PIRCHE AG; *Regeneron Pharmaceuticals, Inc.; REGiMMUNE Corp.; *Sanofi Genzyme; *Seattle Genetics; *Shire; Sobi, Inc.; Spectrum Pharmaceuticals, Inc.; St. Baldrick's Foundation; Swedish Orphan Biovitrum, Inc.; *Takeda Oncology; University of Minnesota; University of Pittsburgh; University of Texas-MD Anderson; University of Wisconsin – Madison and Viracor Eurofins. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government. *Corporate Members. Publisher Copyright: {\textcopyright} 2021 Ferrata Storti Foundation.",
year = "2021",
month = aug,
day = "1",
doi = "10.3324/haematol.2021.279046",
language = "English",
volume = "106",
pages = "2295--2296",
journal = "Haematologica-the Hematology Journal",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "8",
}